Physician profile
Eunbit Ruppert
NPI 1821764077
$3,892.39
in general payments reported to CMS, 2019-2025
13 companies · $2,874 in 2025
The $2,874 reported for 2025 was more than what 97% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $188 · 2024: $831 · 2025: $2,874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,977 · Travel and Lodging: $915.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,977.31 |
| Travel and Lodging | $915.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $1,794.01 | 2025 | Optimizer |
| Boston Scientific Corporation | $528.22 | 2024-2025 | Watchman Flx, Ingevity+ |
| Medtronic, INC. | $510.07 | 2024-2025 | Selectsecure, Cobalt Dr Mri Surescan, Corevalve Evolut R |
| Abbott Laboratories | $315.38 | 2024-2025 | Aveir, Assurity |
| Biotronik INC. | $238.98 | 2025 | Acticor 7 Vr-T Dx, Selectra |
| Pfizer INC. | $193.59 | 2023-2025 | |
| Atricure, INC. | $116.57 | 2023 | |
| Janssen Pharmaceuticals, INC | $56.47 | 2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.77 | 2024-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.10 | 2024-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $22.88 | 2023 | Brilinta |
| Cardiva Medical, INC. | $20.49 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Bayer Healthcare Pharmaceuticals INC. | $13.86 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eunbit Ruppert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.